

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 498/04, A61K 31/535, C07D 513/04 // (C07D 498/04, 267:00, 261:00) (C07D 513/04, 281:00, 261:00)		A1	(11) International Publication Number: WO 96/14321
			(43) International Publication Date: 17 May 1996 (17.05.96)
(21) International Application Number: PCT/EP95/04197		GIL, José Ignacio [ES/ES]; Vesubiana, 22, Getafe Sector 3, E-28905 Madrid (ES). MEERT, Theo, Frans [BE/BE]; Pierstraat 42, B-2840 Rumst (BE). (81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published With international search report.	
(22) International Filing Date: 25 October 1995 (25.10.95)			
(30) Priority Data: 94203177.4 2 November 1994 (02.11.94) EP (34) Countries for which the regional or international application was filed: DE et al. 454,993 31 May 1995 (31.05.95) US			
(60) Parent Application or Grant (63) Related by Continuation US 454,993 (CON) Filed on 31 May 1995 (31.05.95)			
(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): FERNANDEZ-GADEA, Francisco Javier [ES/ES]; Sagra, 20, Cerro de las Perdices, E-45593 Toledo (ES). SIPIDO, Victor, Karel [BE/BE]; Winterkoningstraat 37, B-2170 Merksem (BE). ANDRES-			

(54) Title: SUBSTITUTED TETRACYCLIC OXAZEPINE AND THIAZEPINE DERIVATIVES WITH 5-HT₂ RECEPTOR AFFINITY



(57) Abstract

This invention concerns the compounds of Formula (I), the pharmaceutically acceptable salts and stereoisomeric forms thereof, and also the *N*-oxide forms thereof. In said formula, R¹ and R² each independently are hydrogen; C₁₋₆ alkyl; C₁₋₆ alkylcarbonyl; trihalomethylcarbonyl; C₁₋₆ alkyl substituted with hydroxy, C₁₋₆ alkyloxy, carboxyl, C₁₋₆ alkylcarbonyloxy, C₁₋₆ alkyloxycarbonyl or aryl; or R¹ and R² taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R³ to R¹⁰ each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C₁₋₆alkyl)amino, C₁₋₆ alkylcarbonylamino, aminosulfonyl, mono- or di(C₁₋₆alkyl)-aminosulfonyl, C₁₋₆ alkyl, C₁₋₆ alkyloxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkyloxycarbonyl; R¹¹ is hydrogen, C₁₋₆alkyl, or trifluoromethyl; R¹² is hydrogen, C₁₋₆ alkyl, cyano, or trifluoromethyl; n is zero to 6; and X is O, S, S(=O) or S(=O)₂. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

5 SUBSTITUTED TETRACYCLIC OXAZEPINE AND THIAZEPINE DERIVATIVES WITH
5-HT₂ RECEPTOR AFFINITY


This invention concerns substituted tetracyclic oxazepine and thiazepine derivatives having antipsychotic, cardiovascular and gastrokinetic activity and their preparations; it further relates to compositions comprising them, as well as their use as a medicine.

10

Compounds of similar structure are described in US 4,039,558 which discloses pyrrolidinodibenzo-azepine, -oxazepine, -thiazepine and -diazepine derivatives, having antihistamine, sedative and antidepressant properties. EP-A-0,421,823 describes similar dibenzopyrazino- or benzo-pyrido-pyrazino-azepine derivatives having anti-allergic and anti-asthmatic activities. The present compounds differ therefrom by the presence of an isoxazolidine ring, and by their pharmacological properties.

15

This invention concerns compounds of formula




20

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, and also the *N*-oxide forms thereof, wherein :


R¹ and R² each independently are hydrogen; C₁-6alkyl; C₁-6alkylcarbonyl;

25 trihalomethylcarbonyl; C₁-6alkyl substituted with hydroxy, C₁-6alkyloxy, carboxyl, C₁-6alkylcarbonyloxy, C₁-6alkyloxycarbonyl or aryl; or R¹ and R² taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or a radical of formula :


-2-




(a)




(c)



(e)



(b)



(d)

wherein :

R¹³, R¹⁴, R¹⁵ and R¹⁶ each independently are hydrogen, halo, trifluoromethyl, or C₁₋₆alkyl;

m is 1, 2, or 3;

R¹⁷, R¹⁸, R¹⁹ and R²⁰ each independently are hydrogen or C₁₋₆alkyl; or

R¹⁹ and R²⁰ taken together may form a bivalent radical C₄₋₅alkanediyl;

R²¹ is hydrogen; C₁₋₆alkyl; C₁₋₆alkylcarbonyl; trihalomethylcarbonyl;

C₁₋₆alkyloxycarbonyl; aryl; di(aryl)methyl; C₁₋₆alkyl substituted with hydroxy, C₁₋₆alkyloxy, carboxyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkyloxycarbonyl or aryl ;

R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonylamino, aminosulfonyl, mono- or di(C₁₋₆alkyl)-

aminosulfonyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl;

R¹¹ is hydrogen, C₁₋₆alkyl or trifluoromethyl;

R¹² is hydrogen, C₁₋₆alkyl, cyano or trifluoromethyl;

n is zero, 1, 2, 3, 4, 5, or 6;

X is O, S, S(=O) or S(=O)₂;

aryl is phenyl; or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C₁₋₆alkyl and trifluoromethyl.

In the foregoing definitions C₁₋₆alkyl defines straight and branch chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylpropyl, 1,1-dimethylethyl, pentyl, hexyl; C₄₋₅alkanediyl defines bivalent straight and branch chained saturated hydrocarbon radicals having from 4 to 5 carbon atoms such as, for example, 1,4-butanediyl, 1,5-pentanediy; halo is generic to fluoro, chloro, bromo and iodo.

The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant

-3-

- to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. Said salts can be obtained by treating the base form of the compounds of formula (I) with appropriate acids such as inorganic acids, for example, hydrohalic acid, e.g. hydrochloric or hydrobromic, sulfuric, nitric, phosphoric and the like acids; or organic acids, such as, for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.
- 10 The compounds of formula (I) containing acidic protons may also be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g.
- 15 the benzathine, *N*-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

Conversely said salt forms can be converted into the free forms by treatment with an appropriate base or acid.


20

The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

- 25 The *N*-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide, particularly those *N*-oxides wherein the nitrogen bearing the R¹ and R² substituents is *N*-oxidized.
- 30 The term "stereochemically isomeric forms" as used hereinbefore and hereinafter defines all the possible isomeric forms in which the compounds of formula (I) may occur. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture, in particular the racemic mixture, of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic
- 35 molecular structure. Stereochemically isomeric forms of the compounds of formula (I) and mixtures of such forms are obviously intended to be encompassed by formula (I).

The numbering of the tetracyclic ring-system present in the compounds of formula (I), as defined by Chemical Abstracts nomenclature is shown in formula (I').

-4-



The compounds of formula (I) occur as "*cis*" and "*trans*" isomers. Said terms refer to the position of the substituents on the isoxazolidine ring and are in accordance with Chemical Abstracts nomenclature. The nomenclature is unusual in that carbon atom 3b, being part of a cyclic system, is not considered as a relevant substituent of carbon atom 3a. When establishing the configuration, the substituent on carbon atom 3a (i.e. "Z") and the substituent with the highest priority on carbon atom 2 (i.e. either "T" or "Y") are considered. When "Z" and the substituent with the highest priority on carbon atom 2 are on the same side of the mean plane determined by the isoxazolidine ring then the configuration is designated "*cis*", if not, the configuration is designated "*trans*".

The compounds of formula (I) have at least two asymmetric centers, namely carbon atom 3a bearing the substituent R¹¹ and carbon atom 2 bearing the substituent R¹². Said asymmetric centers and any other asymmetric center which may be present, are indicated by the descriptors R and S.

Whenever used hereinafter, the term compounds of formula (I) is meant to also include the pharmaceutically acceptable acid addition salts, base addition salts and all stereoisomeric forms and also the *N*-oxide forms.

Particular groups of compounds of formula (I) are those wherein one or more of the following restrictions apply :

- a) R¹ and R² each independently are hydrogen, C₁₋₆alkyl, trihalomethylcarbonyl, C₁₋₆alkyl substituted with carboxyl or C₁₋₆alkyloxycarbonyl, or R¹ and R² taken together with the nitrogen atom to which they are attached form a morpholinyl ring or a radical of formula (b), (c), (d), (e);
- b) R¹⁵ and R¹⁶ are hydrogen;
- c) R¹⁷ and R¹⁸ are hydrogen and m is 1 or 2;

-5-

- d) R¹⁹ and R²⁰ are taken together to form a bivalent C₄₋₅alkanediyl radical;
- e) R²¹ is hydrogen, C₁₋₆alkyl, di(aryl)methyl, C₁₋₆alkyloxycarbonyl, trihalomethylcarbonyl, C₁₋₆alkyl substituted with hydroxy, carboxyl, C₁₋₆alkyloxy-carbonyl;
- 5 f) R³, R⁴, R⁵, R⁶ each independently are hydrogen, halo, trifluoromethyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminosulfonyl, carboxyl;
- 10 g) R⁷, R⁸, R⁹, R¹⁰ each independently are hydrogen, halo, trifluoromethyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminosulfonyl, carboxyl;
- h) R¹¹ and R¹² are hydrogen;
- 15 i) X is O, S or S(=O).

Interesting compounds are those compounds of formula (I) or subgroups as defined above, wherein R³, R⁵, R⁶, R⁷, R¹⁰, R¹¹ and R¹² are hydrogen; and in particular, R⁴, R⁸ and R⁹ each independently are selected from C₁₋₆alkyloxycarbonyl and carboxyl,

20 preferably R⁴, R⁸ and R⁹ each independently are selected from hydrogen, halo, trifluoromethyl and C₁₋₆alkylaminosulfonyl.

Also interesting compounds are those compounds of formula (I) or subgroups as defined above, wherein n is 1, 2 or 3 and X is O.

25

Further interesting compounds are those compounds of formula (I) or subgroups as defined above, wherein n is 1 and X is S or S(=O).

More interesting compounds are those interesting compounds in which R¹ and R² each independently are selected from hydrogen, methyl, C₁₋₆alkyl substituted with carboxyl or C₁₋₆alkyloxycarbonyl; or R¹ and R² taken together with the nitrogen atom to which they are attached from a morpholinyl ring or a radical of formula (b), (c) or (e).

30

Preferred compounds are those compounds of formula (I) wherein X is O; n is 1, 2 or 3; R¹ and R² are both methyl, or together with the nitrogen atom to which they are attached form a radical of formula (b) in which R¹⁵ and R¹⁶ are both hydrogen, or a radical of formula (e) in which R²¹ is hydrogen, C₁₋₆alkyl or trifluoromethylcarbonyl; R⁴ and R⁹ each independently are selected from hydrogen, halo, trifluoromethyl, C₁₋₆alkyl-aminosulfonyl; R³, R⁵ to R⁸ and R¹⁰ to R¹² being hydrogen.

35

40

The most preferred compounds are :

-6-

cis-2-[(dimethylamino)methyl]-3,3a-dihydro-*N*-methyl-2*H*-dibenz[b,f]isoxazolo[2,3-d]-[1,4]oxazepine-11-sulfonamide;


cis-11-chloro-3,3a-dihydro-2-(1-piperazinylmethyl)-2*H*-dibenz[b,f]isoxazolo[2,3-d]-[1,4]oxazepine;

5 *cis*-2-[[3,3a-dihydro-11-(trifluoromethyl)-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]oxazepin-2-yl]methyl]-1*H*-isoindole-1,3-(2*H*)-dione; and

cis-11-chloro-3,3a-dihydro-*N,N*-dimethyl-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]-oxazepine-2-propanamine;

the stereochemically isomeric forms and pharmaceutically acceptable acid addition salts thereof, and also their *N*-oxide forms.

Interestingly, the compounds of formula (I) are fairly simple to synthesise. In general, they may be prepared by a 1,3-dipolar cycloaddition of a dienophile of formula (III) and an intermediate of formula (II). In the intermediates (II) and (III) and in any other
 15 intermediate mentioned hereinunder, R¹ to R¹², X and n are as defined hereinabove, unless otherwise indicated. Said 1,3-dipolar cycloaddition may conveniently be carried out by mixing the reactants, optionally in a reaction-inert solvent such as, for example, an aromatic solvent, e.g. toluene; an ether, e.g. tetrahydrofuran, or a mixture of such solvents. Stirring and elevated temperatures, or increased pressure may enhance the rate
 20 of the reaction. The reaction of intermediate (II) with intermediate (III) in practice is regioselective yielding compounds of formula (I).



25 In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, trituration and chromatography.

30 The compounds of formula (I) may also be converted into each other following art-known transformations. For example,

a) a compound of formula (I), wherein R¹ and R² taken together with the nitrogen atom

-7-


- to which they are attached form a radical of formula (b) may be converted into the corresponding primary amine by treatment with hydrazine or aqueous alkali;
- b) a compound of formula (I), wherein R^1 or R^2 is trifluoromethylcarbonyl, may be converted into the corresponding primary or secondary amine by hydrolysis with aqueous alkali;
- 5 c) a compound of formula (I), wherein R^1 or R^2 is C_{1-6} alkyl substituted with C_{1-6} alkylcarbonyloxy may be hydrolyzed into a compound of formula (I) wherein R^1 or R^2 is C_{1-6} alkyl substituted with hydroxy;
- d) a compound of formula (I), wherein R^1 and R^2 are both hydrogen may be mono- or di-*N*-alkylated to the corresponding amine form;
- 10 e) a compound of formula (I), wherein R^1 and R^2 are both hydrogen may be *N*-acylated to the corresponding amide;
- f) a compound of formula (I), containing a C_{1-6} alkyloxycarbonyl group may be hydrolyzed to the corresponding carboxylic acid.
- 15

The compounds of formula (I) wherein X is other than S, may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with 3-phenyl-2-(phenylsulfonyl)-oxaziridine or with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid,

20 peroalkanoic acids, e.g. peroacetic acid, alkylhydroperoxides, e.g. *t*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.


- 30 Intermediates of formula (II) wherein X is O, S(=O) or S(=O)₂, said intermediates are represented by formula (II-a), may be prepared by the oxidation of an intermediate of formula (IV) with a suitable oxidizing agent such as, for example, 2-benzenesulfonyl-3-phenyl-oxaziridine, hydrogen peroxide, *t*-butyl hydroxyperoxide, or metachloroperbenzoic acid.
- 35

-8-



Said oxidation is performed in a reaction-inert solvent at temperatures ranging between -20 °C and 50 °C, preferably between 0 °C and room temperature. Suitable solvents are, for example, water; chlorinated hydrocarbons, e.g. chloroform; aromatic hydrocarbons, e.g. toluene; alcohols, e.g. methanol; ketones, e.g. 4-methyl-2-pentanone; or a mixture of such solvents. When using peroxide oxidants, the reaction rate may be enhanced by using metallic catalysts such as, for example, Na₂WO₄, VO(acetylacetonate)₂, Ti(OBu)₄, and MoO₂(acetylacetonate)₂, optionally under a reaction inert atmosphere such as, for example, argon.

Alternatively, intermediates of formula (II) wherein R¹¹ is hydrogen and R³ to R¹⁰ are defined as hereinabove but other than nitro, said intermediates are represented by formula (II-b), may be prepared by reducing the nitro group of an intermediate of formula (V) in the presence of water and a suitable reducing agent such as, for example, zinc or iron; subsequently followed by an *in situ* intramolecular cyclization in the presence of a weak acid such as, for example, ammoniumchloride or acetic acid. Said reductive cyclization is performed in a reaction-inert solvent such as, for example, 1,4-dioxane. Stirring and elevated temperatures may enhance the rate of the reaction. In intermediate (V), R³ to R¹⁰ are defined as in intermediates of formula (II-b).



Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical

methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.

5 The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or
10 fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the
15 reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The pharmacological activity of the subject compounds is elucidated by one or more of
20 the following tests; *in vitro* 5-HT₂ receptor binding tests; the combined apomorphine, tryptamine and norepinephrine test on rats which is described in Arch. Int. Pharmacodyn., 227, 238-253 (1977); the "mCPP Test on Rats"; and the "Elevated and Illuminated Plus Maze Test on Rats". The latter two tests are both described hereinafter. Additionally, the present compounds show interesting pharmacological activity in the
25 "Tail Suspension Test", and also in the "LSD Drug Discrimination Test" which is described in Drug Dev. Res. 18, 119-144 (1989). Another interesting property of the compounds of formula (I) is that they suppress amphetamine-induced stereotypical behaviour in rats.

30 In view of their pharmacological properties, the compounds of formula (I) are useful as therapeutic agents in the treatment or the prevention of central nervous system disorders like anxiety, depression and mild depression, bipolar disorders, sleep- and sexual disorders, psychosis, borderline psychosis, schizophrenia, migraine, personality disorders or obsessive-compulsive disorders, social phobias or panic attacks, organic
35 mental disorders, mental disorders in children, aggression, memory disorders and attitude disorders in older people, addiction, obesity, bulimia and similar disorders. In particular, the present compounds may be used as anxiolytics, antidepressants and as agents having the potential to overrule the addictive properties of drugs of abuse.

-10-

The compounds of formula (I) may also be used as therapeutic agents in the treatment of motoric disorders. It may be advantageous to use the present compounds in combination with classic therapeutic agents for such disorders.

5

The compounds of this invention may also serve as therapeutic agents in the treatment or the prevention of damage to the nervous system caused by trauma, stroke, neurodegenerative illnesses and the like; cardiovascular disorders like high blood pressure, thrombosis, stroke, and the like; and gastrointestinal disorders like dysfunction of the motility of the gastrointestinal system and the like. The present compounds may also be useful as anticonvulsive agents.

10

In view of the above uses of the compounds of formula (I), it follows that the present invention also provides a method of treating warm-blooded animals suffering from such diseases, said method comprising the systemic administration of a therapeutic amount of a compound of formula (I) effective in treating the above described disorders.

15

The present invention thus also relates to compounds of formula (I) as defined hereinabove for use as a medicine, in particular for use as a medicine to treat the above described disorders.

20

Those of skill in the treatment of such diseases could determine the effective therapeutic daily amount from the test results presented hereinafter. An effective therapeutic daily amount would be from about 0.001 mg/kg to about 10 mg/kg body weight, more preferably from about 0.005 mg/kg to about 1 mg/kg body weight.

25

For ease of administration, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, a therapeutically effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and

30

35

-11-

tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing compounds of formula (I) may be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soy bean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. Acid or base addition salts of compounds of formula (I) due to their increased water solubility over the corresponding base or acid form, are obviously more suitable in the preparation of aqueous compositions.

In order to enhance the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions, it can be advantageous to employ α -, β -, γ -cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl- β -cyclodextrin. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

-12-

The following examples are intended to illustrate and not to limit the scope of the present invention.

Experimental part

5 A. Preparation of the intermediates

Hereinunder, "EtOAc" means ethylacetate, "DMF" means dimethylformamide and "RT" means room temperature.

Example 1

- 10 a) A mixture of 1-(2-propenyl)piperazine (6.6 g) and ethyl 2-propenoate (11.3 ml) in ethanol (100 ml) was stirred and refluxed for 1 hour 30 minutes. The solvent was evaporated, yielding 9.6 g (80%) of ethyl 4-(2-propenyl)-1-piperazine-propanoate (interm. 1).
- 15 b) A mixture of intermediate 1 (7.5 g) in a hydrochloric acid solution (35%) (20 ml), acetic acid (20 ml) and water (10 ml) was stirred and refluxed for 4 hours. The mixture was cooled on an ice bath and NaOH (50%) was added so the mixture was at a pH of about 6 and the solvent was evaporated. The residue was treated with EtOAc, the precipitate was filtered off and the filtrate evaporated. The oily residue was dissolved in toluene and the solvent was evaporated. The residue was purified by short open column chromatography over silica gel (eluent : CH₂Cl₂/(CH₃OH/NH₃) 8/2). The pure fractions
- 20 were collected and evaporated, yielding 5.3g (81%) of 4-(2-propenyl)-1-piperazinepropanoic acid (interm. 2).

Example 2

- 25 A mixture of 2-hydroxybenzaldehyde (16.7 g) and Al₂O₃/KF (65.5 g) in DMF was heated to 120 °C under a N₂ atmosphere and 4-bromo-1-fluoro-2-nitrobenzene (30 g) in DMF was added. The mixture was stirred at 120 °C for 3 hours. The precipitate was filtered off and the filtrate evaporated. The residue was purified by open column chromatography over silica gel (eluent 1: hexane/CH₂Cl₂/AcOEt 8/1/1; eluent 2: CH₂Cl₂/2-propanone 9/1) and the pure fractions were collected, yielding 26 g (59%) of
- 30 2-(4-bromo-2-nitrophenoxy)benzaldehyde (interm. 3).
- Analogously, 5-chloro-2-(2-nitrophenoxy)benzaldehyde (interm. 4) was prepared.

Example 3

- 35 a) 1,4-dichloro-2-nitrobenzene (31.6 g) was added to a mixture of 2,2'-dithiodi-benzaldehyde (41 g) and potassium carbonate (41.3 g) in methanol (820 ml) and the reaction mixture was stirred and refluxed for 2 hours. More 1,4-dichloro-2-nitrobenzene (31.6 g) was added and the reaction mixture was stirred and refluxed for 2 hours. Water was added and the mixture was extracted with CH₂Cl₂. The separated organic layer was

-13-

evaporated and the residue was purified by open column chromatography over silica gel (eluent: hexane/EtOAc 97.5/2.5). The pure fractions were collected and the solvent evaporated, yielding 37 g (84%) of 2-[(4-chloro-2-nitrophenyl)thio]benzaldehyde (interm. 5).

5 Analogously, 2-[[2-nitro-4-(trifluoromethyl)phenyl]thio]benzaldehyde (interm. 6) was prepared.

b) A mixture of potassium peroxymonosulphate (35.6 g) in water (120 ml) was added dropwise to a mixture of intermediate 5 (8.5 g) in methanol (120 ml) cooled on an ice bath and the mixture was stirred at RT for 7 hours. The solvent was evaporated, water
10 was added and the precipitate was filtered off. The residue was purified by flash chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 98/2). The pure fractions were collected and evaporated, yielding 4.8 g (51%) 2-[(4-chloro-2-nitrophenyl)sulfinyl]-benzaldehyde (interm. 7).

15 Example 4

a) LiAlH₄ (1M) in tetrahydrofuran (100 ml) was added dropwise to a mixture of 3-chlorodibenz[b,f][1,4]oxazepin-11(10H)-one (12.3 g) (prepared as described in Indian J. Chem. 1974, 12(3), 227-35) in 1,4-dioxane (400ml) under a N₂ atmosphere. The mixture was stirred, refluxed for 1 hour 30 minutes, cooled and water was added
20 dropwise. The mixture was acidified and extracted with EtOAc. The organic layer was dried with Na₂SO₄, filtered off and evaporated. The residue was purified by open column chromatography over silica gel (eluent : CH₂Cl₂). The pure fractions were collected and evaporated, yielding 9.74 g (84%) of 3-chloro-10,11-dihydrodibenz[b,f]-[1,4]oxazepine (interm.8).

25 b) 3-Phenyl-2-(phenylsulfonyl)oxaziridine (36.4 g) was added to a mixture of intermediate 8 (15.4 g) in trichloromethane (700 ml) and the mixture was stirred at RT for 1 hour. The solvent was evaporated and the residue was purified by open column chromatography over silica gel (eluent : CH₂Cl₂). The pure fractions were collected and evaporated, yielding 8.6 g (34%) of 3-chlorodibenz[b,f][1,4]oxazepine,10-oxide
30 (interm. 9).

Example 5


A mixture of intermediate 3 (10 g) and zinc (10.3 g) in 1,4-dioxane (200 ml) and water (15 ml) was stirred at RT. Ammonium chloride (4.3 g) in water (17 ml) was added
35 dropwise at a temperature below 25 °C and the mixture was stirred at RT for 1 hour. The precipitate was filtered off and the filtrate evaporated. The residue was treated with water and extracted with CH₂Cl₂/CH₃OH 9/1. The organic layer was dried, filtered off and evaporated. The residue was purified by open column chromatography over silica

-14-

gel (eluent 1: CH₂Cl₂/hexane/EtOAc 5/4/1; eluent 2: CH₂Cl₂/2-propanone 9/1). The pure fractions were collected and evaporated, yielding 2.2 g (24%) of 8-bromodibenz-[b,f][1,4]oxazepine,10-oxide (interm. 10).

Analogously, there were prepared :

Table 1



Interm. No.	X	R ⁴	R ⁹
10	O	Br	H
11	O	H	Cl
12	O	Cl	H
13	O	CF ₃	H
14	O	CO-O-CH ₃	H
15	O	H	H
16	S	CF ₃	H
17	S=O	Cl	H

10 B. Preparation of compounds of formula (I)

Example 6

A mixture of intermediate 15 (2.6 g) and *N,N*-dimethyl-2-propen-1-amine (2.9 ml) in toluene (40 ml) was stirred at 80°C for 2 hours. The solvent was evaporated and the residue purified by column chromatography over silica gel (eluent : hexane/CH₂Cl₂/

15 CH₃OH 3.5/6/0.5). The pure fractions were collected and evaporated. The residue was converted into the oxalic acid salt (1:1) in C₂H₅OH at RT, yielding 1 g (63%) of (±)-3,3a-dihydro-*N,N*-dimethyl-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]-oxazepine-2-methanamine ethanedioate(1:1); mp. 179.6°C (comp. 1).

20 Example 7

Following the same procedure as in example 6, but using tetrahydrofuran as a solvent, there was also prepared (±)-*cis*-11-chloro-3,3a-dihydro-*N,N*-dimethyl-2*H*-dibenz[b,f]-isoxazolo[2,3-d][1,4]oxazepine-2-methanamine ethanedioate(1:1); mp. 154.4°C (comp. 2).

25

Example 8

A mixture of (\pm)-*cis*-1-[(11-chloro-3,3a-dihydro-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]-oxazepin-2-yl)methyl]-4-(trifluoroacetyl)piperazine (7.1 g), prepared following the procedure of example 7, and potassium carbonate (4.2 g) in methanol (300 ml) and water (43 ml) was stirred at RT for 2 hours. The solvent was evaporated. The residue was treated with water, extracted with CH₂Cl₂ and the separated organic layer was evaporated. The residue (5.1 g) was purified by flash chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 9/1, 8/2 to 7/3) and the pure fractions were collected and evaporated. The residue (4.2g) was converted into the oxalic acid salt (2:3) in C₂H₅OH at room temperature, yielding 3.9 g (47%) of (\pm)-*cis*-11-chloro-3,3a-dihydro-2-(1-piperazinylmethyl)-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]oxazepine ethanedioate(2:3); mp. >250.0°C (comp. 3).

Example 9


(\pm)-Methyl *cis*-2-[(dimethylamino)methyl]-3,3a-dihydro-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]oxazepine-11-carboxylate ethanedioate(1:1) (1.53 g), prepared following the procedure in example 7, in ethanol (60 ml) was added dropwise to a mixture of sodium hydroxide (0.3 g) in water (7.5 ml) and the mixture was stirred and refluxed for 2 hours. The solvent was evaporated in vacuo and the residue was acidified with HCl (4N) to a pH of 3.6. The precipitate was filtered off, dried with P₂O₅ and purified by short pad column chromatography over silica gel (eluent : CH₂Cl₂/ (CH₃OH/NH₃) 7/3). The pure fractions were collected and evaporated and the residue (1g) was treated with CH₂Cl₂/C₂H₅OH/H₂O 25ml/5ml/5ml. The precipitate was filtered off and dried, yielding 0.5 g (38%) of (\pm)-*cis*-2-[(dimethylamino)methyl]-3,3a-dihydro-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]oxazepine-11-carboxylic acid hemihydrate; mp. 229.8°C (comp. 4).

Example 10

A mixture of (\pm)-*cis*-2-[[3,3a-dihydro-11-(trifluoromethyl)-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]oxazepin-2-yl)methyl]-1*H*-isoindole-1,3(2*H*)-dione (2.53 g), prepared following the procedure of example 7, and hydrazine hydrate (0.28 ml) in ethanol (30 ml) was stirred at 80°C for 5 hours. The precipitate was filtered off and the filtrate evaporated. The oily residue (3.3 g) was purified by flash chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 9.5/0.5). The pure fractions were collected and evaporated, and the oily residue (0.7 g) was converted into the oxalic acid salt (1:1) in C₂H₅OH at RT, yielding 0.8 g (35%) of (\pm)-*cis*-3,3a-dihydro-11-(trifluoromethyl)-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]oxazepine-2-methanamine ethanedioate(1:1); mp. 250°C (comp. 5).

-16-

Tables 2 to 5 list compounds that were prepared in a similar way as in one of the hereinabove mentioned examples.


Table 2

5

Co. No.	Ex. No.	n	X	R ¹	R ²	R ⁴	R ⁸	R ⁹	Physical data (mp. in °C)
1	6	1	O	CH ₃	CH ₃	H	H	H	±-cis/(COOH) ₂ /179.6
2	7	1	O	CH ₃	CH ₃	Cl	H	H	±-cis/(COOH) ₂ /154.4
4	9	1	O	CH ₃	CH ₃	COOH	H	H	±-cis/1/2H ₂ O/229.8
5	10	1	O	H	H	CF ₃	H	H	±-cis/(COOH) ₂ /250.0
6	9	1	O	H	CH ₃	CF ₃	H	H	±-cis/(COOH) ₂
7	7	1	O	CH ₃	CH ₃	F	H	H	±-cis/(COOH) ₂ /181.3
8	7	2	O	CH ₃	CH ₃	Cl	H	H	±-cis/(COOH) ₂ /186.9
9	7	3	O	CH ₃	CH ₃	Cl	H	H	±-cis/(COOH) ₂ /164.3
10	7	6	O	CH ₃	CH ₃	Cl	H	H	±-cis/72.5
11	7	1	O	CH ₃	CH ₃	H	H	Cl	±-cis/(COOH) ₂ /181.5
12	7	1	O	CH ₃	CH ₃	H	Cl	H	±-cis/(COOH) ₂ /163.9
13	7	1	O	CH ₃	CH ₃	Br	H	H	±-cis/(COOH) ₂ /152.6
14	7	1	O	CH ₃	CH ₃	CF ₃	H	H	±-cis/(COOH) ₂ /177.8
15	7	2	O	CH ₃	CH ₃	CF ₃	H	H	±-cis/(COOH) ₂ /197.1
16	7	1	O	CH ₃	CH ₃	COOCH ₃	H	H	±-cis/(COOH) ₂ /152.4
17	7	1	O	CH ₃	CH ₃	SO ₂ NHCH ₃	H	H	±-cis/(COOH) ₂ /78.2
18	7	2	S	CH ₃	CH ₃	H	H	H	±-cis/105.8
19	7	1	S	CH ₃	CH ₃	Cl	H	H	±-cis/113.0
20	7	1	S	CH ₃	CH ₃	CF ₃	H	H	±-(cis+trans)/107.4
21	7	1	SO	CH ₃	CH ₃	Cl	H	H	±-(cis+trans)/144.7
22	7	1	O	CH ₃	CH ₂ -COOH	Cl	H	H	±-cis/H ₂ O/86.2
23	7	1	O	CH ₃	CH ₂ COOCH ₃	Cl	H	H	±-cis/(COOH) ₂ /148.1
24	7	1	O	CH ₃	(CH ₂) ₂ COOH	Cl	H	H	±-cis/ 1/2 H ₂ O/57.3

Co. No.	Ex. No.	n	X	R ¹	R ²	R ⁴	R ⁸	R ⁹	Physical data (mp. in °C)
25	7	1	O	CH ₃	(CH ₂) ₂ COOC ₂ H ₅	Cl	H	H	±-cis/ 3/2 fumaric acid/147.3
26	7	1	O	CH ₃	(CH ₂) ₃ COOH	Cl	H	H	±-cis/(COOH) ₂ /157.2
27	7	1	O	CH ₃	(CH ₂) ₃ COOC ₂ H ₅	Cl	H	H	±-cis/(COOH) ₂ /149.8
28	7	1	O	CH ₃	(CH ₂) ₄ COOH	Cl	H	H	±-cis/(COOH) ₂ /170.1
29	7	1	O	CH ₃	(CH ₂) ₄ COOC ₂ H ₅	Cl	H	H	±-cis/(COOH) ₂ /155.4
30	9	1	O	CH ₃	(CH ₂) ₂ COOH	H	Cl	H	±-cis/159.5
31	7	1	O	CH ₃	(CH ₂) ₂ COOC ₂ H ₅	H	Cl	H	±-cis
32	7	1	O	CH ₃	(CH ₂) ₄ COOH	H	Cl	H	±-cis/(COOH) ₂ /148.4
33	7	1	O	CH ₃	(CH ₂) ₄ COOC ₂ H ₅	H	Cl	H	±-cis/(COOH) ₂ /132.5
34	7	1	O	CH ₃	(CH ₂) ₄ COOH	CF ₃	H	H	±-cis/(COOH) ₂
35	7	1	O	CH ₃	CO-CF ₃	CF ₃	H	H	±-cis


Table 3



5

Co. No.	Ex. No.	R ⁴	R ¹⁹	Physical data (mp. in °C)
3	8	Cl	H	±-cis/ 3/2 (COOH) ₂ />250.0
36	7	Cl	CH ₃	±-cis/ 2 (COOH) ₂ /189.4
37	7	Cl	(CH ₂) ₂ -OH	±-cis/ 2 (COOH) ₂ />250.0
38	7	Cl	CO-CH ₃	±-cis/ 1/2 H ₂ O/46.8
39	7	Cl	CO-O-t-C ₄ H ₉	±-cis/124.7
40	7	Cl	CO-CF ₃	±-cis/110.9
41	7	Cl	(CH ₂) ₂ -COOH	±-cis/H ₂ O/59.2
42	7	Cl	(CH ₂) ₂ -COOC ₂ H ₅	±-cis/ 3/2 (COOH) ₂ /266.6
43	7	Cl	3-chlorophenyl	±-cis/154.5
44	7	Cl	diphenylmethyl	±-cis/198.4
45	7	Cl	bis(4-fluorophenyl)methyl	±-cis/107.2
46	7	F	CH ₃	±-cis/ 2 (COOH) ₂ /186.2
47	7	CF ₃	CH ₃	±-cis/ 2 (COOH) ₂

Table 4



Co. No.	Ex. No	n	X	R ⁴	Q	Physical data (mp. in °C)
48	7	1	O	CF ₃	7,9-dioxo-8-azaspiro[4,5]decan-8-yl	±-cis/149.7
49	7	1	O	CF ₃	1-pyrrolidinyl	±-cis/(COOH) ₂ /174.1
50	7	1	O	Cl	4-morpholinyl	±-cis/(COOH) ₂ >250.0
51	7	1	O	CF ₃	1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl	±-cis/165.6
52	7	2	O	CF ₃	1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl	±-cis/113.9
53	7	3	O	CF ₃	1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl	±-cis/112.2
54	7	1	S	CF ₃	1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl	±-(cis+trans)/135.9

5

C. Pharmacological exampleExample 11 : "mCPP Test on Rats"

Rats were treated with the test compound at a dose varying between 0.0025 mg/kg and 40 mg/kg body weight, at pre-test time T varying between 5 and 480 minutes, and with 10 mg/kg mCPP (metachlorophenylpiperazine), injected intravenously, 15 minutes prior to the test. After pre-test time T elapsed, treated rats were submitted to the "Open Field Test on Rats" as described in Drug Dev. Res. 18, 119-144 (1989), but using an infra-red light source instead of a Kleverlux® (12V/20W) light source. A dose at which 40 % of the tested rats showed suppression of the mCPP induced effects, i.e. mCPP-antagonism, 15 was defined as an active dose. The activity range of a test compound was measured by the ratio of the HAD (highest active dose) over the LAD (lowest active dose). The compounds with number 9 and 11 had a ratio (HAD over LAD) of 4 or more. The compounds with number 2, 3, 5-7, 10, 13, 14, 16, 18-21, 26, 28, 33, 38, 44, 48, 50 and 52 showed mCPP-antagonism at least at one tested dose.

20

Example 12: "Elevated and Illuminated Plus Maze Test on Rats"

The "Elevated and Illuminated Plus Maze Test on Rats" is described in Drug Dev. Res. 18, 119-144 (1989). An active dose of a test compound in said test was defined as a dose at which 40 % of the tested rats explored the illuminated arms of the maze. The 25 activity range was measured similarly as in example 11. The compounds with number 3,

-19-

8, 17, 19, 21, 40, 51, 53 and 54 had a ratio (HAD over LAD) of 4 or more. The compounds with number 1, 2, 4-6, 9-13, 16, 18, 22, 26-30, 32, 33, 36, 39, 41, 43, 44, 46, 47, 49, 50 and 52 showed activity at least at one dose in one or more of the tested rats.

5 **D. Composition examples**

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable acid addition salt, a stereochemically isomeric form thereof or a *N*-oxide form thereof.

Example 13 : ORAL DROPS

- 10 500 Grams of the A.I. was dissolved in 0.5 l of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there were added 35 l of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 grams of sodium saccharin in 2.5 l of purified water and while stirring there were added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing
- 15 an oral drop solution comprising 10 mg/ml of A.I. The resulting solution was filled into suitable containers.

Example 14 : ORAL SOLUTION

- 9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 l of boiling purified water. In 3 l of this solution were dissolved first 10 grams of 2,3-dihydroxybutanedioic acid and thereafter 20 grams of the A.I. The latter solution was combined with the remaining part of the former solution and 12 l 1,2,3-propanetriol and 3 l of sorbitol 70% solution were added thereto. 40 Grams of sodium saccharin were dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of
- 25 gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the active ingredient per teaspoonful (5 ml). The resulting solution was filled in suitable containers.

30 **Example 15 : FILM-COATED TABLETS**

Preparation of tablet core

- A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone in about 200 ml of water. The wet powder mixture was
- 35 sieved, dried and sieved again. Then there was added 100 grams microcrystalline cellulose and 15 grams hydrogenated vegetable oil. The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 mg of the active ingredient.

-20-

.Coating


To a solution of 10 grams methyl cellulose in 75 ml of denaturated ethanol there was added a solution of 5 grams of ethyl cellulose in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 Grams of
5 polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 grams of magnesium octadecanoate, 5 grams of polyvinylpyrrolidone and 30 ml of concentrated colour suspension and the whole was homogenated. The tablet cores were coated with the thus
10 obtained mixture in a coating apparatus.

Example 16 : INJECTABLE SOLUTION

1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxybenzoate were dissolved in about 0.5 l of boiling water for injection. After cooling to about 50°C there were added while stirring 4 grams lactic acid, 0.05 grams propylene glycol and 4 grams
15 of the A.I.. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 l, giving a solution comprising 4 mg/ml of A.I.. The solution was sterilized by filtration and filled in sterile containers.

Claims

1. A compound of formula




5

the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, and also the *N*-oxide forms thereof, wherein :

R^1 and R^2 each independently are hydrogen; C_1 -alkyl; C_1 -alkylcarbonyl;

trihalomethylcarbonyl; C_1 -alkyl substituted with hydroxy, C_1 -alkyloxy, carboxyl,

10 C_1 -alkylcarbonyloxy, C_1 -alkyloxycarbonyl or aryl; or R^1 and R^2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or a radical of formula :



15

wherein :

R^{13} , R^{14} , R^{15} and R^{16} each independently are hydrogen, halo, trifluoromethyl, or C_1 -alkyl;

m is 1, 2, or 3;

20 R^{17} , R^{18} , R^{19} and R^{20} each independently are hydrogen or C_1 -alkyl; or

R^{19} and R^{20} taken together may form a bivalent radical C_{4-5} alkanediyl;

R^{21} is hydrogen; C_1 -alkyl; C_1 -alkylcarbonyl; trihalomethylcarbonyl;

C_1 -alkyloxycarbonyl; aryl; di(aryl)methyl; C_1 -alkyl substituted with hydroxy,

C_1 -alkyloxy, carboxyl, C_1 -alkylcarbonyloxy, C_1 -alkyloxycarbonyl or aryl ;

-22-


- R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonylamino, aminosulfonyl, mono- or di(C₁₋₆alkyl)-aminosulfonyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl;
- 5 R¹¹ is hydrogen, C₁₋₆alkyl or trifluoromethyl;
 R¹² is hydrogen, C₁₋₆alkyl, cyano or trifluoromethyl;
 n is zero, 1, 2, 3, 4, 5, or 6;
 X is O, S, S(=O) or S(=O)₂;
 aryl is phenyl; or phenyl substituted with 1, 2 or 3 substituents selected from halo,
 10 hydroxy, C₁₋₆alkyl and trifluoromethyl.
2. A compound according to claim 1, wherein R³, R⁵, R⁶, R⁷, R¹⁰, R¹¹ and R¹² are hydrogen.
- 15 3. A compound according to claim 2, wherein n is 1, 2 or 3.
4. A compound according to claim 3, wherein R¹ and R² each independently are selected from hydrogen, methyl, C₁₋₆alkyl substituted with carboxyl or C₁₋₆alkyloxy-carbonyl; or R¹ and R² taken together with the nitrogen atom to which they are attached
 20 form a morpholinyl ring or a radical of formula (b), (c) or (e).
5. A compound according to claim 1, wherein the compounds are
cis-2-[(dimethylamino)methyl]-3,3a-dihydro-*N*-methyl-2*H*-dibenz[b,f]isoxazolo[2,3-d]-
 [1,4]oxazepine-11-sulfonamide;
 25 *cis*-11-chloro-3,3a-dihydro-2-(1-piperazinylmethyl)-2*H*-dibenz[b,f]isoxazolo[2,3-d]-
 [1,4]oxazepine;
cis-2-[[3,3a-dihydro-11-(trifluoromethyl)-2*H*-dibenz[b,f]isoxazolo[2,3-d][1,4]oxazepin-
 2-yl)methyl]-1*H*-isoindole-1,3-(2*H*)-dione;
cis-11-chloro-3,3a-dihydro-*N,N*-dimethyl-2*H*-dibenz[b,f]isoxazolo[2,3-
 30 d][1,4]oxazepine-2-propanamine;
 the stereochemically isomeric forms, pharmaceutically acceptable acid addition salts and
 the *N*-oxide forms thereof.
6. A composition comprising a pharmaceutically acceptable carrier and, as active
 35 ingredient, a therapeutically effective amount of a compound as claimed in any one of
 claims 1 to 5.
7. A process of preparing a composition as claimed in claim 6, wherein a
 pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective

-23-

amount of a compound as claimed in any one of claims 1 to 5.

8. Use of a compound as claimed in any one of claims 1 to 5 as a medicine.


5 9. An intermediate of formula



wherein R^3 to R^{11} are defined as in claim 1, an acid or base addition salt thereof or a stereoisomeric form thereof.


10. A process of preparing a compound as claimed in claim 9, characterized in that:

a) an intermediate of formula (IV) wherein R^3 to R^{11} are as defined as in claim 1 and X is O, S(=O) or S(=O)₂, is oxidized with a suitable oxidizing agent, yielding a compound of formula (II-a);




20 b) the nitro group of an intermediate of formula (V) wherein X is defined as in claim 1 and R^3 to R^{10} are defined as in claim 1 but other than nitro, is reduced in the presence of water and a suitable reducing agent, and subsequently an intramolecular cyclization is performed on the thus formed intermediate in the presence of a weak acid, yielding a compound of formula (II-b) wherein X is defined as in claim 1 and R^3 to R^{10} are defined as in claim 1 but other than nitro.

-24-



11. A process of preparing a compound as claimed in claim 1, characterized in that:

5 a) a dienophile of formula (III) is reacted with an intermediate of formula (II) :



10 wherein in the intermediates (II) and (III) R^1 to R^{12} , X and n are defined as in claim 1;

b) converting compounds of formula (I) into each other following art-known transformations, and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or

15 conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing stereochemically isomeric forms or *N*-oxide forms thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 95/04197

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D498/04 A61K31/535 C07D513/04 //(C07D498/04,267:00,
261:00),(C07D513/04,281:00,261:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 17, 1980 PROVO US, pages 341-350, R.B. MOFFETT 'Tetracyclic heterocycles as CNS agents' see the whole document ---	1-11
A	US,A,4 039 558 (VAN DER BURG WILLEM JACOB ET AL) 2 August 1977 cited in the application -----	1-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

29 January 1996

Date of mailing of the international search report

07.02.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

In .ational application No.

PCT/EP 95/ 04197

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 8 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/04197

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4039558	02-08-77	NL-A- 7414038	03-05-76
		BE-A- 834902	27-04-76
		CA-A- 1082182	22-07-80
		DE-A- 2548045	06-05-76
		FR-A, B 2289198	28-05-76
		GB-A- 1530299	25-10-78
		JP-A- 51068598	14-06-76
		SE-A- 7511968	29-04-76
